Advancing patient evidence in XLH (APEX): rationale and design of a real-world XLH global data unification program
X-linked hypophosphatemia (XLH) is a rare, genetic, progressive, lifelong disorder caused by pathogenic variants in the phosphate-regulating endopeptidase homolog, X-linked (PHEX) gene, resulting in excess fibroblast growth factor 23 (FGF23) and consequent renal phosphate wasting. Chronic hypophosph...
Saved in:
| Main Authors: | Maria Luisa Brandi, Thomas O. Carpenter, Seiji Fukumoto, Dieter Haffner, Erik A. Imel, Masanori Kanematsu, Keith P. McCullough, Keiichi Ozono |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-04-01
|
| Series: | Frontiers in Endocrinology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2025.1471127/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Short stature in pre-pubertal children with X-linked hypophosphatemia
by: Hanting Liang, et al.
Published: (2025-05-01) -
Phosphopenic form of osteomalacia in a patient with FGF23 producing tumor
by: A. S. Pushkareva, et al.
Published: (2022-05-01) -
Tumor-induced phosphopenic osteomalacia: modern approaches to diagnostics and treatment
by: A. A. Kondrashov, et al.
Published: (2024-10-01) -
Erratum: X-linked hypophosphatemic rickets and nephrocalcinosis: clinical characteriscs of a single-center pediatric cohort in North America before and after burosumab
by: Frontiers Production Office
Published: (2024-11-01) -
X-linked hypophosphatemic rickets and nephrocalcinosis: clinical characteristics of a single-center pediatric cohort in North America before and after burosumab
by: Neil J. Paloian, et al.
Published: (2024-08-01)